Ayble Health, an AI-powered virtual gastrointestinal clinic, announced on Wednesday that it raised $16 million in Series A funding.
The Boston-based company treats digestive issues including abdominal pain, bloating, constipation, weight gain and more. It offers access to a care team, nutrition tools, gut-brain behavioral therapy and wellness support. The company serves employers, payers and providers.
Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. In total, it has raised more than $27 million.
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
“I’ve been tracking the GI space closely for years, and what Ayble has built is different,” said Kimmy Scotti, founding and managing partner at Neon, in a statement. “Having invested early in top digital health companies, I’ve seen what it takes to build a category-defining company in healthcare. Ayble has spent years building the clinical evidence before they scaled the business. That earns trust from the full ecosystem: health systems, payers, and most importantly, patients, and it’s what makes a durable market leader.”
The financing will be deployed across three main areas, according to Sam Jactel, founder and CEO of Ayble Health.
“First, we are advancing our machine learning capabilities to deliver deeper, data-driven personalization across patient enrollment, engagement, and clinical pathways,” Jactel told MedCity News. “Second, we are expanding our multidisciplinary care model beyond GI into adjacent therapeutic areas, starting directly with autoimmune conditions like rheumatoid arthritis, psoriasis and autoimmune thyroid disorders. Finally, we are accelerating our commercial footprint to scale access across national health plans, jumbo employers, and key benefit platforms.”
Currently, GI conditions affect more than 70 million Americans and drive $136 billion in annual U.S. healthcare spending. Autoimmune conditions add about $106 billion a year in direct U.S. healthcare spend. And patients often experience wait times of up to 40 days for specialty visits.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
In addition, these conditions overlap with other diseases. A 2025 study of 141 million patients found that inflammatory bowel disease was associated with 24 distinct autoimmune conditions.
“Traditional healthcare treats these conditions in isolated silos with 10-minute specialty visits,” Jactel said. “But as any patient will tell you, chronic conditions don’t exist in a vacuum, and they certainly don’t stop when you leave the doctor’s office. Ayble solves this by building an evidence-based, multidisciplinary model that treats overlapping gut and autoimmune conditions under one unified platform.”
Other GI companies include Oshi Health, Cylinder Health and Digbi Health.
Photo: MirageC, Getty Images